Drug intelligence / Profile preview

LY01019

Development stage: Unknown
Lead developer: Boan Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

LY01019 is a recombinant humanized monoclonal antibody targeting Claudin 18.2 (CLDN18.2), developed by Shandong Boan Biotechnology, a subsidiary of Luye Pharma. CLDN18.2 is a tight junction protein that is highly expressed in various solid tumors, including gastric, gastroesophageal junction, and pancreatic cancers, while its expression in normal tissues is strictly limited to the gastric mucosa. LY01019 exerts its anti-tumor effects by binding specifically to CLDN18.2 on the surface of tumor cells, thereby inducing antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The drug is currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, aiming to provide a targeted therapeutic option for patients with CLDN18.2-positive malignancies.

Other names: recombinant humanized anti-CLDN18.2 monoclonal antibody

Targets

Claudin 18.2

Beyond the preview

Go deeper on LY01019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY01019.

Explore the full profile